Saturday, March 2, 2024

CATEGORY

BMS

BMS’s Opdivo Accepted for Supplemental Biologics Application in Lung Cancer by US and EU Authorities

Bristol Myers Squibb's neoadjuvant Opdivo combined with chemotherapy for resectable stage IIA to IIIB non-small cell lung cancer (NSCLC) treatment received FDA acceptance for...

Remarkable Progress in Colorectal Cancer Treatment by Opdivo Plus Yervoy Combo

Bristol Myers Squibb (BMS) has unveiled groundbreaking results from the Phase 3 CheckMate -8HW trial, marking a significant advancement in the treatment of microsatellite...

Repotrectinib in Lung Cancer Treatment: EMA’s Validation Signals Hope

Bristol Myers Squibb achieves a milestone as the European Medicines Agency (EMA) validates their marketing authorization application for repotrectinib, a next-generation tyrosine kinase inhibitor...

Bristol Myers’ $14 Billion Gamble: Acquiring Karuna for Groundbreaking Schizophrenia Treatment

Bristol Myers Squibb is making waves in the pharmaceutical world with its $14 billion acquisition of Karuna Therapeutics, signifying confidence in Karuna's experimental schizophrenia...

Abecma Secures First CAR T Approval for Multiple Myeloma in Japan

Bristol-Myers Squibb K.K. announced approval for Abecma® (idecabtagene vicleucel) in Japan, marking its expanded use in patients with relapsed or refractory multiple myeloma (RRMM)...

FDA Grants Approval to Augtyro™ (Repotrectinib) for ROS1-Positive Lung Cancer

In a groundbreaking development, Bristol Myers Squibb has received approval from the U.S. Food and Drug Administration (FDA) for Augtyro™ (repotrectinib), a next-generation Tyrosine...

Bristol Myers Squibb to Engage in the 2023 UBS BioPharma Conference

Bristol Myers Squibb (BMS) has confirmed its participation in the 2023 UBS BioPharma Conference, scheduled to take place in Miami Beach, Florida, on Wednesday,...

Bristol Myers Squibb’s Opdivo Immunotherapy Combo Shows Promise for Urothelial Carcinoma Treatment in Europe

Bristol Myers Squibb (NYSE: BMY) has taken a significant step toward the approval of Opdivo (nivolumab) in combination with cisplatin-based chemotherapy as a first-line...

Breakthrough Therapy Designation Granted to Potential Pulmonary Fibrosis Treatment

Bristol Myers Squibb (BMS) has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its investigational drug, BMS-986278, which is...

Latest news

Sticky Image